NW 002
Alternative Names: NW-002Latest Information Update: 15 Jan 2024
At a glance
- Originator Chipscreen Biosciences
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 02 Jan 2024 Early research in Solid tumours in China (unspecified route), prior to January 2024 (Chipscreen Biosciences pipeline, January 2024).